CN101563102B - 治疗内皮功能障碍的方法 - Google Patents

治疗内皮功能障碍的方法 Download PDF

Info

Publication number
CN101563102B
CN101563102B CN200780039878.4A CN200780039878A CN101563102B CN 101563102 B CN101563102 B CN 101563102B CN 200780039878 A CN200780039878 A CN 200780039878A CN 101563102 B CN101563102 B CN 101563102B
Authority
CN
China
Prior art keywords
gly
thrombin
asp
amino acid
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200780039878.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN101563102A (zh
Inventor
D·H·卡尼
B·奥尔斯泽维斯卡-帕泽德雷克
T·W·福萨姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Texas A&M University
Original Assignee
University of Guelph
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Guelph, University of Texas System filed Critical University of Guelph
Publication of CN101563102A publication Critical patent/CN101563102A/zh
Application granted granted Critical
Publication of CN101563102B publication Critical patent/CN101563102B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6429—Thrombin (3.4.21.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
CN200780039878.4A 2006-09-22 2007-09-21 治疗内皮功能障碍的方法 Active CN101563102B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US84641806P 2006-09-22 2006-09-22
US60/846,418 2006-09-22
US84800406P 2006-09-28 2006-09-28
US60/848,004 2006-09-28
US92264607P 2007-04-10 2007-04-10
US60/922,646 2007-04-10
PCT/US2007/020445 WO2008036387A2 (en) 2006-09-22 2007-09-21 Method of treating endothelial dysfunction

Publications (2)

Publication Number Publication Date
CN101563102A CN101563102A (zh) 2009-10-21
CN101563102B true CN101563102B (zh) 2014-12-17

Family

ID=39201107

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780039878.4A Active CN101563102B (zh) 2006-09-22 2007-09-21 治疗内皮功能障碍的方法

Country Status (7)

Country Link
US (2) US8334259B2 (enExample)
EP (1) EP2063910A2 (enExample)
JP (2) JP2010504336A (enExample)
CN (1) CN101563102B (enExample)
CA (1) CA2663547C (enExample)
TW (1) TWI486168B (enExample)
WO (1) WO2008036387A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2155236A1 (en) * 2007-04-10 2010-02-24 The Board of Regents,The University of Texas System Combination therapy for cardiac revascularization and cardiac repair
WO2009120307A2 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
EP2268304A2 (en) * 2008-03-26 2011-01-05 Orthologic Corp. Methods for treating acute myocardial infarction
AU2009229395A1 (en) 2008-03-26 2009-10-01 The Board Of Regents, The University Of Texas System Method of treating degenerative diseases
US20110117075A1 (en) * 2008-03-26 2011-05-19 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
GB0916576D0 (en) 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
CA2802176A1 (en) * 2010-06-11 2011-12-15 The Board Of Regents, The University Of Texas System Methods of mitigating effects of radiation and reducing the risk of systemic infection
US10220078B2 (en) 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma
US10881686B2 (en) 2017-10-27 2021-01-05 Zeta Biolongevity, Inc Compositions and methods for treating and preventing proteinuria and endothelial erosion
US10905738B2 (en) * 2018-07-05 2021-02-02 Biozeus Desenvolvimento De Produtos Biofarmacêuticos Synthetic peptides, prodrugs, pharmaceutical compositions and uses
CN113092756A (zh) * 2019-12-23 2021-07-09 首都医科大学附属北京世纪坛医院 尿液凝血酶原及其多肽片段在过敏性疾病中的应用
WO2021207411A1 (en) * 2020-04-07 2021-10-14 Chrysalis Biotherapeutics Tp508 acute therapy for patients with respiratory virus infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061689A1 (en) * 2002-01-16 2003-07-31 The Board Of Regents, The University Of Texas System Thrombin derived peptides for promoting cardiac tissue repair

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
US5244460A (en) * 1991-11-27 1993-09-14 The United States Of America As Represented By The Department Of Health And Human Services Method to foster myocardial blood vessel growth and improve blood flow to the heart
EP0697883A1 (en) 1993-04-29 1996-02-28 Washington University Use of platelet-derived growth factor to improve collateral circulation
ATE273322T1 (de) * 1995-10-24 2004-08-15 Chemo Sero Therapeut Res Inst Tfpi-verwandte peptide die das wachstums von glatten muskelzellen inhibieren
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
US6197751B1 (en) * 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
US6033436A (en) * 1998-02-17 2000-03-07 Md3, Inc. Expandable stent
JP2002512200A (ja) 1998-04-17 2002-04-23 アンジオジェニックス， インコーポレイテッド 治療的な脈管形成因子およびその使用方法
CA2340593C (en) 1998-10-26 2012-05-08 Kari Alitalo Use of vegf-c or vegf-d gene or protein to prevent restenosis
US6363938B2 (en) * 1998-12-22 2002-04-02 Angiotrax, Inc. Methods and apparatus for perfusing tissue and/or stimulating revascularization and tissue growth
TWI257307B (en) * 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
CN1458974A (zh) * 2000-07-20 2003-11-26 德克萨斯系统大学董事会 用非蛋白质水解激活的凝血酶受体的激动剂刺激软骨生长
EP1539800B1 (en) * 2002-07-02 2007-05-23 Orthologic Corp. Thrombin peptide derivative dimers
AU2003256343B2 (en) * 2002-07-02 2006-12-21 Orthologic Corp. Thrombin peptide derivatives
DE602004005564T2 (de) * 2003-12-31 2007-12-13 Orthologic Corp., Tempe Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003061689A1 (en) * 2002-01-16 2003-07-31 The Board Of Regents, The University Of Texas System Thrombin derived peptides for promoting cardiac tissue repair

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jean Davignon et al..Role of Endothelial Dysfunction in Atherosclerosis.《Circulation》.2004,第109卷III-27-III-32. *
John J. Bosnjak et al..Mechanism of thrombin-induced vasodilation in human coronary arterioles.《Am J Physiol Heart Circ Physiol》.2002,第284卷H1080-H1086. *

Also Published As

Publication number Publication date
WO2008036387A3 (en) 2008-12-04
WO2008036387A8 (en) 2008-06-26
CN101563102A (zh) 2009-10-21
WO2008036387A2 (en) 2008-03-27
US8334259B2 (en) 2012-12-18
JP2013166774A (ja) 2013-08-29
EP2063910A2 (en) 2009-06-03
CA2663547C (en) 2020-08-25
CA2663547A1 (en) 2008-03-27
TWI486168B (zh) 2015-06-01
JP2010504336A (ja) 2010-02-12
US20130130978A1 (en) 2013-05-23
TW200829267A (en) 2008-07-16
US20090304671A1 (en) 2009-12-10

Similar Documents

Publication Publication Date Title
CN101563102B (zh) 治疗内皮功能障碍的方法
JP4722290B2 (ja) 結合組織成長因子（ｃｔｇｆ）断片とそれを用いた方法および使用
Ballard et al. Vascular tenascin‐C regulates cardiac endothelial phenotype and neovascularization
US20100330028A1 (en) Combination therapy for chronic dermal ulcers
US20100158907A1 (en) Connective tissue growth factor fragments and methods and uses thereof
US20100303793A1 (en) Combination therapy for cardiac revascularization and cardiac repair
TW200302280A (en) Combination of a growth factor and a protease enzyme
US20060172943A1 (en) Restoring vascular function
JP2017513944A (ja) 異常な皮膚瘢痕化の治療
US8293231B2 (en) Methods and compositions for treating ischemia
US20060002969A1 (en) Methods for reducing the foreign body reaction
US7935341B2 (en) Antibodies to complementary peptides of thrombin or portions thereof
KR20110046911A (ko) 혈관신생 억제 활성을 갖는 펩타이드 및 이의 용도
EP2289542A1 (en) Treatment of neurological or neurodegenerative disorders
KR101228668B1 (ko) 혈관신생 억제 활성을 갖는 펩타이드 및 이의 용도
WO2004111088A2 (en) Angiogenic factor and inhibitors thereof
Phillips et al. Modulation of angiogenesis: experimental strategies and potential therapeutic applications
Sacchi Highly tunable delivery of matrix-bound growth factors for therapeutic angiogenesis
JP2010047549A (ja) ペプチド、細胞接着伸展剤、ガン転移防止剤、及び、遺伝子
ANTITHROMBIN III et al. ENDOTHELIN B RECEPTORS ON HUMAN ENDOTHELIAL CELLS AND SMOOTH MUSCLE CELLS SHOW EQUIVALENT BINDING PHARMACOLOGY
Lin CCN3-induced activities in cutaneous wound healing, angiogenesis, and proliferative restenosis
Colige et al. LABORATORY OF CONNECTIVE TISSUES BIOLOGY
Romain Cooperation Between Carboxy-Terminal Domains of VEGF-A Dictates its Biological Properties in Vitro and in Vivo

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYST

Free format text: FORMER OWNER: APEX TREATMENT INC.

Effective date: 20130222

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Arizona, USA

Applicant after: Vertex therapeutics Inc.

Applicant after: Texas A&M University System

Address before: Arizona, USA

Applicant before: Osorogis Ltd.

Applicant before: Texas A&M University System

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: ORTHOLOGIC CORP. TO: APEX TREATMENT INC.

TA01 Transfer of patent application right

Effective date of registration: 20130222

Address after: Texas, USA

Applicant after: BOARD OF REGENTS University OF TEXAS SYSTEM

Applicant after: Texas A&M University System

Address before: Arizona, USA

Applicant before: Vertex therapeutics Inc.

Applicant before: Texas A&M University System

C14 Grant of patent or utility model
GR01 Patent grant